Status:
COMPLETED
Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease
Lead Sponsor:
Universidade Estadual Paulista Júlio de Mesquita Filho
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
In Brazil, patients with Alzheimer's disease (AD) receiving free drugs of government. Even having access to, little is known about the effectiveness, safety and adherence of drug therapy in this group...
Detailed Description
Dementia is characterized by memory loss associated with cognitive impairment, which directly interferes in learning process, social and professional performance, besides being the main cause of demen...
Eligibility Criteria
Inclusion
- Elderly patients who are assisted in CRIA, diagnosed with Alzheimer's in use of rivastigmine or donepezil or galantamine, assisted by the "Program for special drugs".
- Be resident in the city of Araraquara / SP
- Accept part of pharmacotherapeutic follow-up;
- Sign the Statement of Informed Consent Form (ICF).
Exclusion
- Fold over pharmacotherapy follow-up;
- Being institutionalized;
- Patients unable to respond to collection instruments MMSE and CDR data;
- Patient without phone contact.
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT02222181
Start Date
April 1 2014
End Date
March 1 2016
Last Update
May 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Referência do Idoso de Araraquara - CRIA
Araraquara, São Paulo, Brazil, 14800240